TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

20A.66 Le Tiec C et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44:1035-50. 20A.67 Fuster D et al. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother 2005;6:1565-72. 20A.68 Havlir DV et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004;38:1599- 604. 20A.69 Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther 2003; 1:403-13. 20A.70 European Medicines Agency (EMA). European assessment report (EPAR). Prezista, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000707/WC500041756.pdf. Accessed on August 20 th 2010. 20A.71 Back D et al. Darunavir: pharmacokinetics and drug interactions. Antiviral Ther 2008;13:1-13. 20A.72 Fenton C et al. Darunavir in the treatment of HIV-1 infection. Drugs 2007;67:2791-801. 20A.73 El-Atrouni WI et al. Darunavir. Drugs Today 2007;43:671-9. 20A.74 McCoy C. Darunavir: A nonpeptidic antiretroviral protease inhibitor. Clin Ther 2007;29:1559-76. 20A.75 Rittweger M et al. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739-56. 20A.76 Molina JM et al. Darunavir: a nonpeptidic antiretroviral protease inhibitor. Expert Opin Pharmacother 2007;8:1951-64. 20A.77 European Medicines Agency (EMA). European assessment report (EPAR). Telzir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_- _Product_Information/human/000534/WC500035345.pdf. Accessed on August 20 th 2010. 20A.78 Torres HA et al. Fosamprenavir plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 2007;5: 349-63. 20A.79 Arvieux C et al. Amprenavir or fosamprenavir plus ritonavir in HIV infection. Pharmacology, efficacy and tolerability profile. Drugs 2006;65:633-59. 20A.80 Chapman TM et al. Fosamprenavir. A review of its use in the management of antiretroviral therapynaive patients with HIV infection. Drugs 2004;64:2101-24. 20A.81 Wire MB et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45:137-68. 20A.82 Becker S et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Expert Opin Pharmacother 2004;5:1995-2005. 20A.83 Hester EH et al. Fosamprenavir: drug development for adherence. Ann Pharmacother 2006;40: 1301-10. 20A.84 European Medicines Agency (EMA). European assessment report (EPAR). Crixivan, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000128/WC500035730.pdf. Accessed on August 20th 2010. 20A.85 Rayner CR et al. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother 2002; 36:1230-7. 20A.86 Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 2007;8:957-64. 20A.87 Plosker GL et al. Indinavir. A review of its use in the management of HIV infection. Drugs 1999;58: 1165-203. 20A.88 Wu DS et al. Indinavir urolithiasis. Curr Opin Urol 2000;10:557-61. 20A.89 Famularo G et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000;34: 1414-8. 20A.90 Yeh KC et al. Single dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332-8. 20A.91 Colson AE et al. Paronychia in association with indinavir treatment. Clin Infect Dis 2001;32:140-3. 20A.92 Florence E et al. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Ann Rheum Dis 2002;61:82-4. 20A.93 European Medicines Agency (EMA). European assessment report (EPAR). Kaletra, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000368/WC500039043.pdf. Accessed on August 20 th 2010. 20A.94 Tan D et al. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert Rev Anti Infect Ther 2007;5:13-28. 20A.95 Walmsley S et al. The role of lopinavir/ritonavir in the management of HIV infected adults. Expert Rev Anti Infect Ther 2003;1:389-401. 20A.96 Barragan P et al. Lopinavir/ritonavir: a protease inhibitor for HIV-treatment. Expert Opin Pharmacother 2008;9:2363-75. 20A.97 von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today 2007;43:221-47. 20A.98 Oldfield V et al. Lopinavir/ritonavir. A review of its use in the management of HIV infection. Drugs 2006;66:1275-99. 20A.99 Kaplan SS et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005;56:273-6. 20A.100 Vogel M et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. Expert Opin Drug Saf 2005;4:403-20. 20A.101 Corbett AH et al. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002:36:1193-203. 20A.102 European Medicines Agency (EMA). European assessment report (EPAR). Viracept, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000164/WC500050679.pdf. Accessed on August 20 th 2010. 20A.103 Perry CM et al. Nelfinavir. A review of its use in the management of HIV infection. Drugs 2005;65: 2209-44. 20A.104 Tebas P et al. Nelfinavir mesylate. Expert Opin Pharmacother 2000;1:1429-40. 20A.105 European Medicines Agency (EMA). European assessment report (EPAR). Norvir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000127/WC500028728.pdf. Accessed on August 20 th 2010.. 20A.106 Zeldin RK et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9. 20A.107 Cooper CL et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92. 20A.108 Rathbun RC et al. Low-Dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002;36:702-6. 20A.109 European Medicines Agency (EMA). European assessment report (EPAR). Invirase, summary of pro-
duct characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000113/WC500035084.pdf. Accessed on August 20 th 2010. 20A.110 Johnson M et al. Saquinavir/low-dose ritonavir: its use in HIV infection. AIDS Rev 2003;5:44-51. 20A.111 Plosker GL et al. Saquinavir. A review of its use in boosted regimens for treating HIV infection. Drugs 2003;63:1299-324. 20A.112 European Medicines Agency (EMA). European assessment report (EPAR). Aptivus, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000631/WC500025936.pdf. Accessed on August 20 th 2010. 20A.113 Courter JD et al. Tipranavir: a new protease inhibitor for the pediatric population. Expert Rev Anti Infect Ther 2008;6:797-803. 20A.114 Temesgen et al. Tipranavir: a new option for the treatment of drug-resistant HIV Infection. Clin Infect Dis 2007;45:761-9. 20A.115 Luna B et al. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 2007;29:2309-18. 20A.116 King JR et al. Tipranavir. A novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665-82. 20A.117 Dong BJ et al. Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 2006;40: 1311-21. 20A.118 Temesgen Z et al. Tipranavir. Drugs Today 2005;41:711-20. 20A.119 Croom KF et al. Tipranavir. A ritonavir-boosted protease inhibitor. Drugs 2005;65:1669-77. 20A.120 Kandula VR et al. Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev Anti Infect Ther 2005;3:9-21. 20A.121 Mehandru S et al. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 2003;12:1821-8. 20A.122 Justice AC et al. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis 2008;47:1226-30. 20A.123 Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003;34(suppl. 1):S91-4. 20A.124 European Medicines Agency (EMA). European assessment report (EPAR). Ziagen, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000252/WC500050343.pdf. Accessed on August 20 th 2010. 20A.125 Hervey PS et al. Abacavir. A review of its clinical potential in patients with HIV infection. Drugs 2000; 60:447-79. 20A.126 Yuen GJ et al. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47:351-71. 20A.127 Saag M et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-8. 20A.128 Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568- 79. 20A.129 Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006;43:99-102. 20A.130 Hughes CA et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008;42:387-96. 20A.131 Clay PG et al. Management protocol for abacavir-related hypersensitivity raction. Ann Pharmacother 2000;34:247-9. 20A.132 Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14. 20A.133 Behrens GM et al. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010;23:9-14. 20A.134 D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26. 20A.135 Moreno S et al. Didanosine enteric-coated capsule current role in patients with HIV-1 infection. Drugs 2007;67:1441-62. 20A.136 European Medicines Agency (EMA). European assessment report (EPAR). Emtriva, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000533/WC500055586.pdf. Accessed on August 20 th 2010. 20A.137 Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006;42:126-31. 20A.138 Frampton JE et al. Emtricitabine. A review of its use in the management of HIV infection. Drugs 2005; 65:1427-48. 20A.139 Molina JM et al. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today 2005; 41:241-52. 20A.140 Modrzejewski KA et al. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother 2004;38:1006-14. 20A.141 Cahn P. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2004;13:55-68. 20A.142 European Medicines Agency (EMA). European assessment report (EPAR). Epivir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000107/WC500027572.pdf. Accessed on August 20 th 2010. 20A.143 Bessesen M et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28: 1032-5. 20A.144 Sellier P et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. Scand J Infect Dis 2004;36:533-5. 20A.145 European Medicines Agency (EMA). European assessment report (EPAR). Zerit, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro duct_Information/human/000110/WC500049165.pdf. Accessed on August 20 th 2010. 20A.146 Cheer SM et al. Stavudine once daily. Drugs 2002;62:2667-74. 20A.147 Joly V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16:2447-54. 20A.148 Boubaker K et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis 2001;33:1931-7. 20A.149 Coghlan ME et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-21. 20A.150 European Medicines Agency (EMA). European assessment report (EPAR). Viread, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22:
1.873 Korting HC et al. Current top
Page 23 and 24:
1.970 Thomas RJ et al. Current mana
Page 25 and 26:
of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77: tients. J Antimicrob Chemother 2009
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?